AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10097996 — intervention group
Group type: EXPERIMENTAL
Intervention: TOM test in older children
Number of subjects: 70
Study 10097996 — intervention group
Group type: EXPERIMENTAL
Intervention: TOM test in normal children (n = 12)
Number of subjects: 70
Study 10097996 — intervention group
Group type: EXPERIMENTAL
Intervention: TOM test in children with PDDs (n = 10)
Number of subjects: 70
Study 10097996 — intervention group
Group type: EXPERIMENTAL
Intervention: TOM test in children with PDDs (n = 20)
Number of subjects: 70
Study 10097996 — intervention group
Group type: EXPERIMENTAL
Intervention: TOM test scores
Number of subjects: 70
Study 10097996 — intervention group
Group type: EXPERIMENTAL
Intervention: TOM test
Number of subjects: 70
Study 8901129 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg morphine hydrochloride as Vendal retard film tablets
Number of subjects: 24
Study 8901129 — intervention group
Group type: COMPARATOR
Intervention: 30 mg morphine sulphate as Mundidol retard film tablets
Number of subjects: 24
Study 1794831 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelomyrtol forte
Number of subjects: 20
Study 1794831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6621017 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacoustically similar hearing aids
Number of subjects: 0
Study 6621017 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacoustically heterogeneous hearing aids
Number of subjects: 0
Study 6621017 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard monosyllabic word lists
Number of subjects: 0
Study 6621017 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative hearing aid evaluation
Number of subjects: 0
Study 31892355 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperPath
Number of subjects: 4
Study 31892355 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 4
Study 31892355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 4
Study 30557342 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRP3
Number of subjects: 86
Study 30557342 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRP9
Number of subjects: 86
Study 30557342 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1
Number of subjects: 86
Study 27095446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat load test meal (OFTT) with 0.7 g fat/kg body weight (12% SFA, 10% PUFA, 43% MUFA, 10% protein, 25% carbohydrates)
Number of subjects: 1002
Study 27095446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat load test meal (OFTT)
Number of subjects: 1002
Study 24767004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control therapy (CCT) + active transcranial direct current stimulation (tDCS)
Number of subjects: 37
Study 24767004 — intervention group
Group type: COMPARATOR
Intervention: Cognitive control therapy (CCT)
Number of subjects: 37
Study 21805294 — intervention group
Group type: EXPERIMENTAL
Intervention: Celastrus orbiculatus extract (COE) at concentrations of 10, 20, 40, 80, and 160 μg/mL
Number of subjects: 0
Study 20667751 — intervention group
Group type: EXPERIMENTAL
Intervention: A-V impulse technology (A-V)
Number of subjects: 36
Study 20667751 — intervention group
Group type: COMPARATOR
Intervention: Compression stocking (CS)
Number of subjects: 36
Study 20667751 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-operation
Number of subjects: 36
Study 17443478 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN‐alfa‐2a
Number of subjects: 133
Study 17443478 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alfa‐2a
Number of subjects: 133
Study 17443478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic growth factors
Number of subjects: 133
Study 17443478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose modifications for nonhematologic toxicity
Number of subjects: 133
Study 15309001 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4902
Study 15309001 — intervention group
Group type: COMPARATOR
Intervention: No Aspirin
Number of subjects: 4902
Study 15309001 — intervention group
Group type: EXPERIMENTAL
Intervention: Withheld Aspirin
Number of subjects: 4902
Study 12040470 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg starting on the day of infusion)
Number of subjects: 241
Study 12040470 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg starting five days later)
Number of subjects: 241
Study 12040470 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF (Control Group)
Number of subjects: 241
Study 12040470 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (both arms A and B)
Number of subjects: 241
Study 12040470 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF on day 0 vs day +5
Number of subjects: 241
Study 11352697 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 30
Study 11352697 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 9408713 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual subject random assignment clinical trials
Number of subjects: 0
Study 9408713 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study 9408713 — intervention group
Group type: COMPARATOR
Intervention: Community randomized trials
Number of subjects: 0
Study 9408713 — intervention group
Group type: COMPARATOR
Intervention: Clinical trials of pharmacologic agents
Number of subjects: 0
Study 8505479 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 26
Study 8505479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8505479 — intervention group
Group type: COMPARATOR
Intervention: Non-ADHD controls
Number of subjects: 26
Study 3555036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin therapy (750 to 2,250 mg daily, mean 1,800 mg)
Number of subjects: 18
Study 3555036 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (tobramycin or azlocillin)
Number of subjects: 18
Study 31181990 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) formulation of cilostazol
Number of subjects: 0
Study 31181990 — intervention group
Group type: COMPARATOR
Intervention: Sustained Release (SR) formulation of cilostazol
Number of subjects: 0
Study 29374327 — intervention group
Group type: EXPERIMENTAL
Intervention: Local tranexamic acid
Number of subjects: 37
Study 29374327 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostasis measures (Control)
Number of subjects: 37
Study 28044948 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS Group
Number of subjects: 83
Study 28044948 — intervention group
Group type: COMPARATOR
Intervention: Standard Group
Number of subjects: 83
Study 23906190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg) from 1 day before to 14 days after surgery
Number of subjects: 236
Study 23906190 — intervention group
Group type: COMPARATOR
Intervention: No tamsulosin treatment (control group)
Number of subjects: 236
Study 23906190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin treatment
Number of subjects: 236
Study 23906190 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin treatment and control
Number of subjects: 236
Study 23697477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical counseling of hospital medical staff and additional information in the discharge letter for the PCP
Number of subjects: 240
Study 20977584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 20977584 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg LC15-0444
Number of subjects: 145
Study 20977584 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg LC15-0444
Number of subjects: 145
Study 20977584 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg LC15-0444
Number of subjects: 145
Study 20977584 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of LC15-0444
Number of subjects: 145
Study 18940296 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based high-intensity aerobic interval training (exercise group, n = 40), exercised twice a week for 4 months plus 4 consultations with a CHF nurse.
Number of subjects: 80
Study 18940296 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40), no specific intervention mentioned.
Number of subjects: 80
Study 15794797 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 200
Study 15794797 — intervention group
Group type: COMPARATOR
Intervention: Open donor nephrectomy (ODN)
Number of subjects: 200
Study 12641613 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatone Iron‐Plus (48 ml)
Number of subjects: 102
Study 12641613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 10595595 — intervention group
Group type: EXPERIMENTAL
Intervention: UL-TG 307 (24 mg daily)
Number of subjects: 13
Study 10595595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8767527 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CDA)
Number of subjects: 80
Study 8767527 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (FAMP)
Number of subjects: 80
Study 8767527 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (CLB)
Number of subjects: 80
Study 8767527 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-CDA and FAMP
Number of subjects: 80
Study 8767527 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMP and 2-CDA
Number of subjects: 80
Study 8767527 — intervention group
Group type: EXPERIMENTAL
Intervention: Purine analogs
Number of subjects: 80
Study 1678570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bunazosin hydrochloride
Number of subjects: 0
Study 1678570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (contralateral eyes)
Number of subjects: 0
Study 30551783 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm band
Number of subjects: 50
Study 30551783 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow sleeve
Number of subjects: 50
Study 30551783 — intervention group
Group type: COMPARATOR
Intervention: No brace
Number of subjects: 50
Study 28304200 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE technique
Number of subjects: 67
Study 28304200 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 67
Study 26603970 — intervention group
Group type: EXPERIMENTAL
Intervention: African ancestry RGA increase (0.10)
Number of subjects: 149
Study 26603970 — intervention group
Group type: EXPERIMENTAL
Intervention: European ancestry RGA increase (0.10)
Number of subjects: 149
Study 26603970 — intervention group
Group type: EXPERIMENTAL
Intervention: African RGA tertiles (6%‐66%)
Number of subjects: 149
Study 26603970 — intervention group
Group type: EXPERIMENTAL
Intervention: African RGA tertiles (67%‐86%)
Number of subjects: 149
Study 25052785 — intervention group
Group type: EXPERIMENTAL
Intervention: In-prison substance use and depression treatments
Number of subjects: 60
Study 25052785 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-release support network
Number of subjects: 60
Study 21928226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged prednisolone therapy (5-month)
Number of subjects: 80
Study 19497441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2111
Study 17660645 — intervention group
Group type: EXPERIMENTAL
Intervention: Airotor
Number of subjects: 150
Study 17660645 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 150
Study 17660645 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 150
Study 15222602 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch treatments (6 sessions)
Number of subjects: 0
Study 11755284 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical food bar enriched with L-arginine and other nutrients
Number of subjects: 36
Study 9842980 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of cisapride (10 mg per unit, 20 mg total dose)
Number of subjects: 0
Study 9842980 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of cisapride (10 mg per unit, 20 mg total dose)
Number of subjects: 0
Study 7856298 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms hepatitis B vaccine
Number of subjects: 174
Study 7856298 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms hepatitis B vaccine
Number of subjects: 174
Study 7856298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosages of hepatitis B vaccine
Number of subjects: 174
Study 2504532 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothroid
Number of subjects: 18
Study 2504532 — intervention group
Group type: COMPARATOR
Intervention: Synthroid
Number of subjects: 18
Study 320929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune globulin
Number of subjects: 30
Study 320929 — intervention group
Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 30
Study 31239328 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy for anterior AIS in patients aged <80 years
Number of subjects: 20
Study 31239328 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy for anterior AIS in patients aged ≥80 years
Number of subjects: 20
Study 30730866 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium (40 mg) combined with TAP block (150 mg of 0.375% ropivacaine with 5 mg dexamethasone)
Number of subjects: 100
Study 30730866 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium combined with TAP block
Number of subjects: 100
Study 30730866 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 mg) without TAP block
Number of subjects: 100
Study 28787431 — intervention group
Group type: EXPERIMENTAL
Intervention: Left side TIVAD implantation
Number of subjects: 240
Study 28787431 — intervention group
Group type: COMPARATOR
Intervention: Right side TIVAD implantation
Number of subjects: 240
Study 25504506 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide transarterial chemoembolization and intravenous administration of arsenic trioxide
Number of subjects: 139
Study 25504506 — intervention group
Group type: COMPARATOR
Intervention: Arsenic trioxide transarterial chemoembolization
Number of subjects: 139
Study 22865778 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroma-high (>50%)
Number of subjects: 710
Study 22865778 — intervention group
Group type: COMPARATOR
Intervention: Stroma-low (≤50%)
Number of subjects: 710
Study 20921922 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg intravenously) administered at anesthetic induction
Number of subjects: 38
Study 19318461 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing anticholinergic load from symptom-specific medications
Number of subjects: 304
Study 19318461 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing anticholinergic load
Number of subjects: 304
Study 16505800 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-adhesive 0.2% chlorhexidine gel applied once after extraction
Number of subjects: 30
Study 16505800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorhexidine gel)
Number of subjects: 30
Study 16505800 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (chlorhexidine gel)
Number of subjects: 30
Study 14959876 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia tutorial
Number of subjects: 174
Study 14959876 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study 11414873 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-implemented treatments designed to experimentally increase intentional communication ability
Number of subjects: 58
Study 9072480 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 166
Study 9072480 — intervention group
Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 166
Study 9072480 — intervention group
Group type: COMPARATOR
Intervention: Diabetics on CAPD
Number of subjects: 166
Study 9072480 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetics on CAPD
Number of subjects: 166
Study 8302763 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg oral dose of fadrozole hydrochloride
Number of subjects: 18
Study 8302763 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg oral dose of fadrozole hydrochloride
Number of subjects: 18
Study 8302763 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg oral dose of fadrozole hydrochloride
Number of subjects: 18
Study 8302763 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride (all doses)
Number of subjects: 18
Study 8302763 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride
Number of subjects: 18
Study 2896796 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate with sodium cromoglycate eye drops (Beconase and Opticrom)
Number of subjects: 640
Study 2896796 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (Depo‐Medrone)
Number of subjects: 640
Study 2896796 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (Hismanal)
Number of subjects: 640
Study 2896796 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (Triludan)
Number of subjects: 640
Study 2896796 — intervention group
Group type: COMPARATOR
Intervention: Mequitazine (Primalan)
Number of subjects: 640
Study 2896796 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine maleate (Piriton)
Number of subjects: 640
Study 2896796 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate nasal insufflation with xylometazoline/antazoline eye drops (Rynacrom and Otrivine‐Antistin)
Number of subjects: 640
Study 2896796 — intervention group
Group type: COMPARATOR
Intervention: Azatadine maleate (Optimine)
Number of subjects: 640
Study 2896796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethothiazine (Banistyl)
Number of subjects: 640
Study 31550915 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU of intramuscular vitamin D
Number of subjects: 70
Study 31550915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27775998 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone at induction and 250 mg methylprednisolone before cardiopulmonary bypass
Number of subjects: 555
Study 27775998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 26247968 — intervention group
Group type: EXPERIMENTAL
Intervention: Chia oil (16 mL daily) from the third trimester of pregnancy until the first six months of nursing
Number of subjects: 40
Study 26247968 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal feeding
Number of subjects: 40
Study 23438946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (5 mg) in CYP3A5 expressers
Number of subjects: 0
Study 23438946 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 23438946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 21527202 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% testosterone propionate ointment twice daily for 30 days before surgery
Number of subjects: 26
Study 21527202 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 26
Study 19623047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 523
Study 19623047 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels < or =1.2 mmol/L
Number of subjects: 523
Study 16418786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate (10 mg daily)
Number of subjects: 64
Study 16418786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15054349 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.4 g/day larch arabinogalactan (n=18)
Number of subjects: 74
Study 15054349 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.4 g/day tamarack arabinogalactan (n=19)
Number of subjects: 74
Study 15054349 — intervention group
Group type: COMPARATOR
Intervention: Placebo of rice starch (n=17)
Number of subjects: 74
Study 11198705 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of intramuscular thiamin
Number of subjects: 107
Study 11198705 — intervention group
Group type: COMPARATOR
Intervention: Other doses of intramuscular thiamin
Number of subjects: 107
Study 10211007 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC (1.1%) of isoflurane in oxygen for 30 min followed by 1 MAC (2.1%) of sevoflurane in oxygen for 30 min
Number of subjects: 28
Study 10211007 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC (2.1%) of sevoflurane in oxygen for 30 min followed by 1 MAC (1.1%) of isoflurane in oxygen for 30 min
Number of subjects: 28
Study 10211007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia in subgroup with pulmonary artery catheters (n = 12)
Number of subjects: 28
Study 10211007 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia in subgroup with pulmonary artery catheters (n = 12)
Number of subjects: 28
Study 8166187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified management
Number of subjects: 1145
Study 8166187 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 1145
Study 8166187 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic control
Number of subjects: 1145
Study 3139325 — intervention group
Group type: EXPERIMENTAL
Intervention: 6,000 units pro‐urokinase i.c. (group H)
Number of subjects: 144
Study 3139325 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 units pro‐urokinase i.c. (group L)
Number of subjects: 144
Study 3139325 — intervention group
Group type: EXPERIMENTAL
Intervention: 960,000 IU urokinase i.c. (group U)
Number of subjects: 144
Study 29044725 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide therapy
Number of subjects: 0
Study 29044725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27487573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Psychotherapy (DT)
Number of subjects: 237
Study 27487573 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 237
Study 24743460 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based sensorimotor training program (45 mins, 5 days/week for 8 weeks)
Number of subjects: 12